Indivior Closes Out a Long-Running Suboxone Antitrust Case With a $385 Million Settlement

With a $385 million settlement, Suboxone maker Indivior is moving to wrap up years of antitrust litigation tied to its opioid addiction treatment.

The company will shell out the money to resolve long-running claims from a group of direct purchasers, Indivior said Monday.

Once approved by the U.S. District Court for the Eastern District of Pennsylvania, the case will officially be closed. Indivior will likely pay up next month, the company said in a release.

Read the source article at Fierce Pharma